Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Lumora Raises $1.1M to Support Technology Commercialization

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Lumora today said it raised £700,000 ($1.1 million) in a follow-on financing as the company plans on further commercializing its technology in the US and Europe.

Current investors Tate & Lyle Ventures, Catapult Ventures Managers, and Cambridge University participated in the financing, which the Cambridge, UK-based firm said will go toward efforts to further commercialize its diagnostic technologies and applications, including the BART (Bioluminescent Assay in Real Time) system. BART is a reporter system for use with isothermal nucleic acid amplification technologies.

"During this quarter we have made significant progress with a number of commercial deals and the funding will allow us to further develop new products, take advantage of new opportunities, and accelerate existing commercial agreements," Laurence Tisi, CEO of Lumora, said in a statement.

In the spring of 2011, Lumora raised $2.1 million in second-stage funding.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.